Rafferty Asset Management
PDLI

Rafferty Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Rafferty Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-91,817
Closed -$289K – 1078
2020
Q3 		$289K Buy
91,817
+41,405
+82% +$132K ﹤0.01% 826
2020
Q2 		$147K Buy
+50,412
New +$159K ﹤0.01% 954
2019
Q3 		– Sell
-263,979
Closed -$829K – 879
2019
Q2 		$829K Buy
263,979
+63,858
+32% +$207K 0.01% 593
2019
Q1 		$744K Buy
+200,121
New +$676K 0.01% 597

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
Gabelli Funds
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
Context Capital Management
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
Winton Group
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Hancock Whitney
Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

Rafferty Asset Management's PDLI Position: Q4 2020 in Review

Rafferty Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 91,817 shares — an estimated $289K sold.

Rafferty Asset Management first reported a position in PDLI in Q1 2019 and held it in 4 quarters. The position peaked at $829K in Q2 2019. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Rafferty Asset Management reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Rafferty Asset Management sold 91,817 PDL BioPharma, Inc. shares in Q4 2020, an estimated $289K.
  • Rafferty Asset Management first reported a position in PDL BioPharma, Inc. in Q1 2019 and held it in 4 quarters.
  • Rafferty Asset Management's PDL BioPharma, Inc. position peaked at $829K in Q2 2019.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Rafferty Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.